The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy-Reference-Cited by-同舟云学术

The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy

Published:2022-12 Issue: Volume:156 Page:113839
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Basak Edwin A.,de Joode Karlijn,Uyl Tom J.J.,van der Wal Ronald,Schreurs Marco W.J.,van den Berg Sjoerd A.A.,Oomen-de Hoop Esther,van der Leest Cor H.,Chaker Layal,Feelders Richard A.,van der Veldt Astrid A.M.,Joosse Arjen,Koolen Stijn L.W.,Aerts Joachim G.J.V.,Mathijssen Ron H.J.,Bins Sander

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference26 articles.

1. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation;Freeman;J. Exp. Med,2000

2. K.-. investigators, Pembrolizumab versus Ipilimumab in Advanced Melanoma;Robert;N. Engl. J. Med,2015

3. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer;Brahmer;N. Engl. J. Med,2015

4. K.-. Investigators, Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma;Bellmunt;N. Engl. J. Med,2017

5. I. CheckMate, Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma;Motzer;N. Engl. J. Med,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria;Diseases;2024-02-14

2. Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab;BMJ Case Reports;2023-04

3. Ipilimumab/nivolumab/pembrolizumab;Reactions Weekly;2023-04-01